compound, pharmaceutical composition and dlk inhibition method, method of treating a dlk-mediated disease, method of treating cancer and reducing the development of a chemotherapy-induced neurological disorder and method for achieving an effect in a patient
GANG LIU,JASON CROSS,KANG LE,MICHAEL J. SOTH,PHILIP JONES
申请号：
BR112019011801
公开号：
BR112019011801A2
申请日:
2017.12.08
申请国别(地区):
BR
年份:
2019
代理人:
摘要：
Disclosed herein are compounds which inhibit the activity of double leucine zipper kinase (dlk) kinase (map3k12), pharmaceutical compositions and methods for treating dlk-mediated diseases, such as neurological disorders resulting from traumatic injury to neurons of the central nervous system and peripheral nervous system (eg stroke, traumatic brain injury, spinal cord injury), or resulting from a chronic neurodegenerative disorder (eg alzheimer's disease, frontotemporal dementia, parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, lewy body disease, kennedy disease and other related disorders), neuropathies resulting from neurological injury (chemotherapy-induced peripheral neuropathy, diabetic neuropathy and related disorders) and cognitive disorders caused by pharmacol intervention (eg, chemotherapy-induced cognitive impairment, also known as chemotherapy fog).são revelados no presente documento compostos que inibem a atividade de quinase da quinase de zíper de leucina dupla (dlk) (map3k12), composições farmacêuticas e métodos para tratamento de doenças mediadas por dlk, tais como doenças neurológicas que resultam de lesão traumática em neurônios do sistema nervoso central e sistema nervoso periférico (por exemplo, derrame, lesão cerebral traumática, lesão na medula espinhal), ou que resultam de uma afecção neurodegenerativa crônica (por exemplo, doença de alzheimer, demência frontotemporal, doença de parkinson, doença de huntington, esclerose lateral amiotrófica, ataxia espinhocerebelar, paralisia supranuclear progressiva, doença com corpos de lewy, doença de kennedy e outras afecções relacionadas), de neuropatias que resultam de lesão neurológica (neuropatia periférica induzida por quimioterapia, neuropatia diabética e afecções relacionadas) e de distúrbios cognitivos provocados por intervenção farmacológica (por exemplo, distúrbio cognitivo induzido por quimioterapia, também conhecid
